Histopathology of non-mass-like breast lesions on ultrasound.
Breast
Calcification
Carcinoma in situ
Non-mass-like lesion
Ultrasound
Journal
Journal of medical ultrasonics (2001)
ISSN: 1613-2254
Titre abrégé: J Med Ultrason (2001)
Pays: Japan
ID NLM: 101128385
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
30
09
2022
accepted:
30
11
2022
medline:
21
7
2023
pubmed:
12
2
2023
entrez:
11
2
2023
Statut:
ppublish
Résumé
There have been several investigations of non-mass-like (NML) lesions on ultrasound (US) since Uematsu first described this approach, and it is a relatively new concept for breast examination. However, the results have varied, and there have been only a few studies related to the detailed histopathology of NML lesions on US. Here, we review the histopathology of NML lesions. NML lesions are pathologically benign, atypical, or malignant. There are two major findings of NML lesions on US: architectural distortion and calcifications. Architectural distortion pathologically indicates a fibrous change with ductal proliferation, invasive breast carcinoma, and carcinoma in situ. Histopathologically, microcalcifications are seen in both benign and malignant lesions, and it is important to distinguish between these lesions among NML lesions, particularly fibrocystic changes including adenosis and hyperplasia in the case of benign lesions and carcinoma in situ (ductal and lobular) in the case of malignant lesions. The differential major points may be whether NML lesions are associated with abundant hyperechoic foci, which indicate comedo necrosis on histology. They are usually high-grade carcinoma in situ that may be positive for HER2 or triple negativity. A recent report indicated that low-grade carcinoma in situ showed better survival than higher-grade carcinoma in situ, which is often accompanied by comedo necrosis on histology, reflecting visible microcalcification on US. NML lesions are considered to include a certain rate of low-grade carcinoma in situ. Therefore, more caution may be needed when detecting and managing NML lesions to avoid overdiagnosis and overtreatment as a result of this recent "low-risk ductal carcinoma in situ" concept.
Identifiants
pubmed: 36773105
doi: 10.1007/s10396-023-01286-y
pii: 10.1007/s10396-023-01286-y
pmc: PMC10354136
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
375-380Informations de copyright
© 2023. The Author(s).
Références
Uematsu T. Non-mass-like lesions on breast ultrasonography: a systematic review. Breast Cancer. 2012;19:295–301.
doi: 10.1007/s12282-012-0364-z
pubmed: 22456924
Tabár L, Tot T, Dean PB. VI Calcifications on mammogram. Teaching atlas of mammography. 4th edition: Thieme, 2012; 170–1.
Yamaguchi R, Tanaka M, Yamaguchi M, et al. Histology of microcalcifications. J Breast Thyroid Sonography. 2017;6:64–7 ((in Japanese)).
Lee J, Lee JH, Baik S, et al. Non-mass lesions on screening breast ultrasound. Med Ultrason. 2016;18:446–51.
doi: 10.11152/mu-871
pubmed: 27981276
Wang ZL, Li N, Li M, et al. Non-mass-like lesions on breast ultrasound: classification and correlation with histology. Radiol Med. 2015;120:905–10.
doi: 10.1007/s11547-014-0493-x
pubmed: 25725790
Park JW, Ko KH, Kim EK, et al. Non-mass breast lesions on ultrasound: final outcomes and predictors of malignancy. Acta Radiol. 2017;58:1054–60.
doi: 10.1177/0284185116683574
pubmed: 28114809
Park KW, Park S, Shon I, et al. Non-mass lesions detected by breast US: stratification of cancer risk for clinical management. Eur Radiol. 2021;31:1693–706.
doi: 10.1007/s00330-020-07168-y
pubmed: 32888070
Kim HR, Jung HK. Histopathology findings of non-mass cancers on breast ultrasound. Acta Radiol Open. 2018;29:2058460118774957.
Watanabe T, Yamaguchi T, Tsunoda H, et al. Ultrasound image classification of Ductal Carcinoma in Situ (DCIS) of the breast: analysis of 705 DCIS lesions. Ultrasound Med Biol. 2017;43:918–25.
doi: 10.1016/j.ultrasmedbio.2017.01.008
pubmed: 28242086
Jin ZQ, Lin MY, Hao WQ, et al. Diagnostic evaluation of ductal carcinoma in situ of the breast: ultrasonographic, mammographic and histopathologic correlations. Ultrasound Med Biol. 2015;41:47–55.
doi: 10.1016/j.ultrasmedbio.2014.09.023
pubmed: 25479813
Morita M, Yamaguchi R, Tanaka M, et al. Two progressive pathways of microinvasive carcinoma: low-grade luminal pathway and high-grade HER2 pathway based on high tumour-infiltrating lymphocytes. J Clin Path. 2016;69:890–8.
doi: 10.1136/jclinpath-2015-203506
pubmed: 27030304
Morita M, Yamaguchi R, Tanaka M, et al. CD8(+) tumor-infiltrating lymphocytes contribute to spontaneous “healing” in HER2-positive ductal carcinoma in situ. Cancer Med. 2016;5:1607–18.
doi: 10.1002/cam4.715
pubmed: 27061242
pmcid: 4944888
Gunawardena DS, Burrows S, Taylor DB. Non-mass versus mass-like ultrasound patterns in ductal carcinoma in situ: is there an association with high-risk histology? Clin Radiol. 2020;75:140–7.
doi: 10.1016/j.crad.2019.10.009
pubmed: 31739979
Sagara Y, Mallory MA, Wong S, et al. Survival benefit of breast surgery for low-grade ductal carcinoma in situ: a population-based cohort study. JAMA Surg. 2015;150:739–45.
doi: 10.1001/jamasurg.2015.0876
pubmed: 26039049
Francis A, Bartlett JMS, Billingham LJ, et al. The LORIS trial: a multicentre, randomized phase III trial of standard surgery versus active monitoring in women with newly diagnosed low risk ductal carcinoma in situ. Cancer Res. 2013;73:OT2–3-01.
Kanbayashi C, Iwata H. Current approach and future perspective for ductal carcinoma in situ of the breast. Jpn J Clin Oncol. 2017;47:671–7.
doi: 10.1093/jjco/hyx059
pubmed: 28486668
pmcid: 5896693